NanoPharmaceuticals (NP) has launched its first-in-human clinical trial with a novel new precision drug, NP751, that was shown to be effective in preclinical models against human glioblastoma (GBM) grafted into animals. The dearth of effective clinical treatment for GBM currently imposes an average survival time of nine months on patients with this cancer, only rising to 15-16 months for those receiving standard-of-care surgery and adjuvant chemotherapy. NP’s Founders have conducted extensive research on a cell surface receptor for thyroid hormone on the plasma membrane, named thyrointegrin αvβ3, that regulates a large number of intracellular signaling pathways essential to cell cycle (cell division) and cancer cell protection from self-destruction, and intercellular signaling pathways that support tumor propagation and tumor angiogenesis.